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ABSTRACT
Cervical cancer is a malignant transformation of keratinocytes initiated by the 
E7 oncoprotein of human papillomavirus (HPV). These tumors are characterized 
by keratinocyte hyperproliferation and are often infiltrated with activated CD8 T 
cells. HPV infection confers changes to gain immunological advantage to promote 
chronic infection, and these persist with malignant transformation. We investigated 
the relative importance of the many redundant mechanisms of cytotoxicity used by 
CD8 T cells to kill keratinocytes expressing HPV E7 oncoprotein using extended-
duration time-lapse microscopy that allows examination of cell-to-cell interactions 
during killing. E7 expression by keratinocytes increased susceptibility to cell-mediated 
killing. However, while killing of non-transgenic keratinocytes was traditional, 
perforin-mediated, and caspase-dependent, E7-expression favored killing by perforin-
independent, caspase-independent mechanisms. The roles of perforin, TNFα, IFNγ, 
Fas/FasL and PD1/PD-L1 were graded according to target cell survival to produce 
a hierarchy of killing mechanisms utilized in killing E7-expressing cells. TNFα was 
essential for perforin-mediated killing of E7-expressing cells, but not perforin-
independent killing. IFNγ facilitated killing by Fas/FasL interaction, especially in the 
absence of perforin. Additionally, expression of E7 offered protection from killing by up 
regulation of PD-L1, Fas and FasL expression on keratinocytes promoting fight-back 
by target cells, resulting in effector cell death. This study shows that keratinocytes 
expressing E7 are highly susceptible to killing by CD8 T cells, but utilizing different 
armamentarium. Down-regulation of CD8 T cell cytotoxicity in HPV-related tumors 
may be due to suppression by E7-expressing keratinocytes. Immunotherapy for HPV-
related cancers may be improved by suppression of PD-L1, or by suppression of FasL.
INTRODUCTION
Persisting human papillomavirus infection is the 
main cause of cervical and anal cancers, and has been 
implicated in a large number of other epithelial tumors 
including skin, esophageal, and head and neck cancers 
[1]. Papillomavirus infects basal replicating keratinocytes 
(KC) and is cleared by the immune system in the majority 
of cases resulting in no further clinical progression. 
In persistent infection, HPV evades clearance by the 
immune system, increasing the risk for oncogenesis 
[2]. HPV proteins E6 and E7 are expressed in all 
cervical cancers, and are responsible for the oncogenic 
progression of lesions by their suppressive action on the 
retinoblastoma gene product, resulting in KC proliferation 
and suppression of differentiation. HPV infection results 
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in maintaining cell cycling, preventing apoptosis, and 
preventing differentiation, due to expression of its two 
major oncoproteins, E6 and E7 [3].
Although the immune system has failed to detect 
and destroy these cells producing non-self, virus-derived, 
oncogenic proteins, these lesions are often associated 
with a marked immune cell infiltrate. The presence 
of CD8 T cells in cervical lesions is associated with 
a favorable prognosis, with their numbers inversely 
correlating with tumor progression [4, 5]. Despite 
infiltrating tumors, however, effector T cells are unable 
to kill their targets [6]. E7-expressing murine skin grafts 
placed on E7-naïve animals, are not rejected [7]. As skin 
graft rejection is CD8 T cell dependent, tolerance of E7-
expressing skin suggests that the E7 oncoprotein plays 
a role in inhibiting cell-mediated immune function in 
cervical cancers.
Persistence and transformation of the basal KC 
by proteins such as E7 is associated with immune 
evasion. Multiple mechanisms of immune evasion within 
transformed KC have been described including Fas down-
regulation [8, 9], downstream effects on apoptosis of down-
regulation of the retinoblastoma gene [10], alteration of the 
processing of IFNγ -dependent intracellular proteins [11, 12, 
13], and changes to the TNF receptor and processing [14]. 
Additionally, the effects of HPV on infiltrating lymphocytes, 
preventing activation [15], affecting mechanisms of 
cytotoxicity, or promoting anergy or exhaustion [15, 16] 
may be due to the expression of E7 oncoprotein.
CD8 T cells have a substantial armamentarium with 
which to kill target cells. Contact-dependent mechanisms 
including perforin/granzyme and Fas-FasL, and contact-
independent mechanisms such as production of TNFα or 
IFNγ – are utilized by CD8 T cells in tumor environments 
with varying degrees of preference.
We examined the mechanisms by which activated 
antigen-specific CD8 T cells may kill keratinocytes 
expressing E7 protein. Using a live-cell imaging-based 
killing assay, we co-cultured primary keratinocytes 
from mice expressing E7 from the keratin-14 promoter 
(E7KC), or from non-transgenic mice (B6KC), loaded 
with OVA, and EGFP+CD8+ effector T cells from OVA-
immunized mice. These studies allowed us to examine 
the interactions between targets and effectors during 
the attachment and killing process and the kinetics of 
killing. E7KC were more susceptible to killing by CD8 
T cells than their non-transgenic counterparts, however, 
it was apparent that effectors were using a different set of 
mechanisms to achieve target death. Additionally, E7KC 
themselves produced proteins such as FasL and PD-L1, 
lethal to cytotoxic T cells. Recently, utilizing an anti-
CD40 antibody to elicit immunization against HPVE6/E7 
successfully primed CD8 T cells to kill papillomavirus-
related tumor cells in vitro [17]. Our data suggest that 
enhancement of effector function may be achieved by 
suppression of immune-inhibitory proteins.
RESULTS
E7 expression alters the kinetics of keratinocyte 
killing
We investigated the effects of expression of HPV 
E7 oncoprotein by primary keratinocytes (KC) on their 
susceptibility to killing by CD8 T cells. K14.E7 mice 
(E7), derived from C57/B6 mice (B6), express HPV E7, 
a major oncoprotein in HPV-related cervical cancer, from 
the keratin-14 promoter. Thus HPV E7 is expressed in 
these mice predominantly by keratinocytes. We isolated 
primary keratinocytes from E7 mice, or from B6 mice, 
loaded them with SIINFEKL peptide, the TCR epitope 
of OVA, and co-cultured with CD8 OT-I T cells, which 
have a TCR receptor specific for SIINFEKL presented 
by H-2b. We found the total CTL-mediated killing of E7-
expressing and non-transgenic KC to be the same over 
30 hours (Figure 1A), which was consistent with other 
studies [19]. However, examining the kinetics of killing, 
B6KC exhibited specific “lag” period before target cell 
death (Figure 1A) which we have seen previously [18], 
while E7-expressing KC did not exhibit any lag period 
before death (Figure 1A), implying these cells may have 
altered killing kinetics. When loaded with the same dose 
of cognate peptide antigen, E7KC were killed earlier than 
non-transgenic cells (Figure 1B). The rate of KC death 
in monocultures and in co-cultures without peptide was 
similar between E7KC and B6KC, less than 7% over 30 
hours (Figure 1C), showing E7 expression does not confer 
longevity on KC in culture. These data indicate that E7-
expressing KC remain susceptible remain susceptible to 
killing by antigen-specific CD8 T cells, but possibly by 
different mechanisms to non-transgenic KC.
Apoptosis of E7-expressing KC can follow a 
caspase-3 independent pathway
Both granule-mediated killing and Fas-mediated 
killing, the two primary contact dependent mechanisms 
used by CTL to kill their targets, predominantly involve 
activation of intracellular caspases, leading to activation of 
caspase 3 and resulting in cell death [20]. We investigated 
whether E7 expression altered the susceptibility of KC to 
be killed by caspase dependent mechanisms. Co-cultures 
of KC and CTL in the presence of FLIVO-SR dye that 
fluoresces red upon activation of intracellular caspases 
were treated with Z-DEVD-FMK, a specific inhibitor of 
caspase-3. Non-transgenic KC showed no progression to 
apoptosis as indicated either by cell morphology or by 
color change (Figure 1D, Supplementary Video 1). E7KC 
also had a marked reduction in the rate of apoptosis. 
However, around 35% of E7KC became apoptotic by 
color change and by morphology (p<0.05) (Figure 1D, E). 
Inhibition of caspase-3 did not affect duration of target-
CTL attachment, which was similar in both E7 and B6KC 
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in the presence of the caspase inhibitor (Figure 1F). We 
conclude that E7KC, but not B6KC, are susceptible to 
apoptosis by caspase-3 independent mechanisms.
E7-expressing KC can be killed by perforin-
independent mechanisms
Antigen-specific killing by CD8 effector cells 
classically occurs by granule-mediated mechanisms, 
which involve perforin-dependent delivery of granzymes 
to the target cell following direct CTL-target cell contact. 
To determine whether perforin is important in mediating 
KC killing by CD8 T cells, we immunized EGFP Prf1-/- or 
EGFP B6 mice with SIINFEKL and isolated CD8 T cells, 
further culturing them with SIINFEKL peptide for three 
days to generate perforin-deficient or perforin-competent 
antigen-specific EGFP+CD8+ CTL of comparable 
activation status as assessed by CD44 and CD62L 
expression (Figure 2A, B). These effector cells were co-
cultured with SIINFEKL-loaded E7KC or B6KC to assess 
target cell killing. In the absence of perforin, killing of 
non-transgenic KC was abrogated to baseline levels, while 
E7KC targets remained partially susceptible to CTL-
mediated killing suggesting perforin was not necessary 
for killing of E7-expressing KC (p=0.02) (Figure 2C, D).
There was a marked reduction in the duration of 
attachment of effector cells to KC targets in the absence of 
perforin regardless of E7 expression (Figure 2E). Perforin-
deficient CTL made numerous short-duration attachments 
to KC targets, lasting less than 60 min, before detaching 
without causing target cell death. However, when perforin-
deficient CTL killed E7-expressing KC, they did so after 
an average attachment time of 18.4 h (± 4.2), compared 
with 13.3 h (± 3.6) for perforin-competent CTL (p=0.04), 
suggesting attachment time is relevant to the mechanism 
of target cell killing. Expression of E7 by KC did not 
affect T cell death rates (Figure 2F).
E7KC are killed by TNFα-dependent and IFNγ-
independent mechanisms
Activated CD8 T cells produce TNFα and IFNγ that 
contribute to their cytotoxic function. We inhibited TNFα 
by incubating co-cultures of target and antigen-loaded 
effector cells with anti-TNFα inhibitory antibody. Anti-
TNFα antibody completely abrogated killing of both E7-
expressing and non-transgenic KC (Figure 3A), without 
affecting duration of cell-to-cell attachment (Figure 3B) 
implying CD8 T cells depend on TNFα to kill target KC. 
Inhibition of TNFα had no effect on death of T cells in the 
co-culture (Figure 3C). Inhibition of IFNγ, on the other 
hand, inhibited killing of B6KC, and partially inhibited 
killing of E7KC (Figure 3D) (B6 cf. E7 p<0.001; E7 
isotype cf. anti-IFNγ p=0.016), also without affecting 
duration of effector cells attachment to targets (Figure 3E). 
Inhibition of IFNγ inhibited T cell death also in co-culture 
Figure 1: E7 expression by keratinocytes alters their susceptibility to killing by CTL. Primary KC were isolated from B6 or 
E7 transgenic mice and loaded with SIINFEKL peptide. EGFP+OT-1 T cells were isolated and co-cultured with skin cells, with indicator 
dye for activated caspases. (A) KC survival over 30 hours of co-culture. Average of 4 experiments shown, error bars represent SD. (B) The 
percentage of KC deaths at 5 hour intervals was determined by counting newly dead cells at each time point and expressing as a fraction of 
the total number of cells in each frame. (C) KC death at 30 hours in co-culture with effector cells (black) or in monoculture (grey). (D) KC 
were incubated with Z-DEVD-FMK or DMSO (Mock) 60 minutes before and during co-culture; death assessed at 30 h. (E) CTL and KC 
co-cultures at 13 h showing attachment of CTL (green) to KC (arrow), and at 30 h showing early apoptosis of KC as indicated by red color 
change. Bar is 10 μm. See also, Supplementary Video 1. (F) Duration of attachments of E7-expressing (E7) or non-transgenic (B6) KC with 
CTL while incubated with DMSO (mock), Z-DEVD-FMK, or without peptide loading. (*p<0.05; n.s. not significant).
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with B6KC, but not with E7KC, attributable to reduced 
antigen-induced cell death in the B6KC–T cell co-cultures 
(Figure 3F).
To confirm the inhibitory antibodies were acting on 
the CTL, rather than on the target cells, we pre-incubated 
the CTL with inhibitory antibody for 4 hours prior to co-
culture with effector T cells. Inhibition of TNFα on CTL 
alone inhibited killing to a similar degree to treatment of 
co-cultures (Figure 3G). Inhibition of IFNγ on CTL, while 
it markedly inhibited killing of B6 cells, only partially 
inhibited killing of E7-expressing KC (Figure 3H), 
suggesting that IFNγ was not sufficient or necessary for 
CTL killing of E7-expressing KC.
E7 expression alters KC susceptibility to CD8 T 
cell killing by Fas/FasL
Fas-FasL interaction is a major mechanism of inter-
lymphocyte fratricide and CTL can express both Fas and 
FasL on their surface. Expression of Fas by tissue cells 
can be bound by CTL-related soluble or membrane-bound 
FasL resulting in target cell apoptosis, and may be an 
important mechanism of killing of tumor cells [21]. It is 
not known how E7 expression by keratinocytes affects 
their susceptibility to killing by the Fas/FasL system.
We incubated KC-CTL co-cultures with inhibitory 
antibody to Fas, or to Fas-L, both of which resulted in a 
significant, but not complete, inhibition of death of B6KC 
(Figure 4A and 4E; p=0.046 anti-Fas c.f. Isotype, p=0.049 
anti-FasL c.f. Isotype). Inhibition of Fas and FasL also 
appeared to abolish the characteristic lag period before 
killing in these cells (Figure 4B, F). Inhibition of Fas 
or FasL reduced the duration of cell-to-cell attachment 
of both wild type and E7 transgenic KC (Figure 4C, G). 
Paradoxically, inhibition of either Fas or FasL caused 
a significant increase in killing of E7-expressing KC 
(Figure 4A, E; p<0.05 anti-Fas or anti-FasL c.f. Isotype). 
As CTL also express Fas, we examined the death rate of 
CD8 T cells in the co-cultures. With inhibition of either 
Fas or FasL, CTL death rate was significantly lower in 
co-cultures with E7KC, but not B6KC (Figure 4D, H), 
suggesting increased availability of cytotoxic T cells may 
be the mechanism by which Fas/FasL inhibition enhanced 
E7KC killing in this assay.
Therefore we examined E7KC and B6KC to determine 
whether E7 expression increased the expression of Fas or 
Figure 2: CD8 T cells kill E7KC by perforin-independent mechanisms. In vivo and in vitro activated OVA-specific EGFP+Prf-
competent and EGFP+Prf1-/- CD8 T cells were added to KC primary cultures. (A) Flow cytometry of wild-type (WT) and perforin-
deficient (Prf1-/-) CD8 T cells pre-gated on size and granularity, and CD8 expression. (B) Percentage of CD44+ cells after gating. Results 
of 4 independent CD8 harvests. (C) Primary KC from E7 and B6 mice were loaded with SIINFEKL and co-cultured with GFP+Prf1-/- CD8 
T cells. KC survival calculated as in Figure 1. (D) The final frames of movies were used to calculate percentage KC death over 30 hours. 
(E) Frequency distribution of the duration of attachments of effector cells to targets at 30-minute intervals. (F) Quantification of T cell death 
in co-cultures with antigen-loaded E7-expressing or non-transgenic KC at 30 hours. (*p<0.05; n.s. not significant).
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FasL on the surface of the cells. Flow cytometry of freshly 
harvested KC showed increased Fas and FasL expression on 
the surface of E7KC compared with wild type KC (Figure 4I, 
J). Confocal microscopy after five days in culture allowing 
protein expression and cell division to recommence, showed 
that, although variability in expression levels between cells in 
the same culture was evident as expected with cycling cells, 
there was a marked increase in surface expression of Fas and 
FasL in E7-transgenic KC (Figure 4K, M). Examination of 
the RNA expression of cultured KC confirmed up-regulation 
of Fas mRNA expression in E7KC compared with wild type 
cells (Figure 4L), although FasL mRNA expression was not 
up regulated suggesting, as have others, that its regulation is 
post-transcriptional [22] (Figure 4N).
These data allow the hypothesis that E7KC are more 
susceptible to apoptosis via Fas on their cell surface, and 
that increased expression of FasL may allow E7KC to kill 
effector T cells.
PD-L1 expression by E7-expressing KC is 
protective
Epithelial cell expression of PD-L1 as with FasL 
expression, has been associated with resistance of tumors 
to T cell mediated killing. PD-L1 is expressed on many 
epithelial cells, usually affording immune protection, as 
interaction with PD-1 on activated T cells leads to down 
regulation of T cell function. We found that inhibition of 
PD-L1 in co-cultures of effector and target cells had little 
effect on killing of non-transgenic KC (Figure 5A; p=0.15 
untreated c.f. anti-PD-L1 in B6KC), but promoted killing 
of KC expressing E7, suggesting up regulation of PD-
L1 as a result of E7 expression contributes to resistance 
to CD8 T cell killing (Figure 5A; p=0.016 E7 c.f. B6; 
p=0.03 untreated c.f. anti-PD-L1 in E7KC). Unlike FasL 
inhibition, PD-L1 inhibition did not affect the duration of 
CTL/target cell attachment (Figure 5B). As the reduced 
killing may have been the result of an increasing ratio 
of effectors to target cells as the culture progressed, we 
investigated whether T cells were failing to die in these 
treated co-cultures. Inhibition of PD-L1 markedly reduced 
the death rate of CTL in E7KC co-cultures, implying that 
some of the CD8 T cell death was attributable to PD-L1 
expressed on the surface of transgenic KC (Figure 5C).
We investigated whether E7 expression on KC 
altered their expression of PD-L1. Freshly isolated E7-
transgenic KCs were subject to surface staining for PD-
L1. We saw a significant increase in the surface expression 
Figure 3: Perforin-competent CD8 effector T cells require TNFα but not IFNγ for cytotoxic function. EGFP+OT-1 T cells 
were incubated with KC loaded with SIINFEKL. (A-C) An inhibitory antibody to TNFα was added to the KC before and during co-culture. 
KC death (A), duration of attachment of effectors to targets (B) and death of effector cells (C) with anti-TNFα or isotype control antibody. 
(D-F) Anti-IFNγ antibody was added to KC before and during co-culture. (D) KC death, duration of attachment (E) of effectors to targets 
and effector cell death (F) with anti-IFNγ or isotype control antibody. (G-H) Effector cells were pre-treated with antibody against TNFα 
(E) or IFNγ (F) before co-culture with target KC. Averages of 5 imaging sites of duplicate wells are shown as a single dot. Each dot is one 
separate experiment. Error bars are SEM. (*p<0.05).
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of PD-L1 by flow cytometry in these cells (Figure 
5D). RT-PCR studies of cultured KC at 7 days showed 
marked increase in PD-L1 RNA expression among E7KC 
compared with non-transgenic cells (Figure 5E).
Hierarchical killing mechanisms used by CTL to 
kill E7-expressing KC
CD8 T cells have been shown to utilize different 
mechanisms of cytotoxicity in a hierarchical, tissue-
dependent manner [23]. In order to investigate how 
E7 oncoprotein expression affected the hierarchy of 
mechanisms used in killing KC, we now combined 
different combinations of the killing mechanisms 
recognized as being relevant to tumor killing to rank the 
importance of each. Not all combinations were included, 
particularly where the primary cytotoxic effect was so 
marked as to render any further effect immeasurable and 
irrelevant.
We co-cultured primary B6 or E7-expressing KC 
loaded with SIINFEKL with OVA-primed effector cells 
from perforin-competent B6 mice or from perforin-
deficient Prf1-/- mice, and inhibited Fas or FasL. Inhibition 
of the Fas pathway abrogated the non-perforin mediated 
Figure 4: CD8 T cells utilize Fas/FasL to kill E7 expressing KC. Co-cultures of effector cells and SIINFEKL-loaded KC were 
treated with inhibitory antibody to Fas (A-D) or FasL (E-H) or isotype control antibodies (iso). (A, E) Death of KC in co-culture (black) 
or monoculture controls (grey). (B, F) Survival kinetics of KC-effector co-cultures. (C, G) Duration of effector-KC attachment. (D, H) 
T cell death rate. Freshly-derived primary KC were examined for Fas (I) or FasL (J) expression by flow cytometry. Gating delineated living 
cells that were CD45 negative. Each value represents one mouse. (K, M) Confocal micrograph (maximal intensity projection) of primary 
KC cultured for 5 days and stained for surface expression of Fas (green) (K) or FasL (red) (M). (L, N) Primary KC were cultured for 
5 days and cell lysates were harvested for RNA extraction. RT-PCR for Fas (L) or FasL (N) mRNA was performed comparing expression 
to a house-keeping gene. Each value represents one mouse. (*p<0.05; n.s not significant; bar is 50μm).
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killing of E7-expressing KC seen in Figure 2 to levels 
similar to that of non-transgenic cells (Figure 6A, B). Fas 
had no protective effect on killing of E7KC in the absence 
of perforin.
Perforin-dependent B6KC killing, which was 
partially reduced by inhibition of PD-L1, was further 
reduced by inhibition of Fas. Similarly, the protective 
effect of PD-L1 on E7KC was not seen in the absence of 
perforin as inhibition of PD-L1 resulted in abrogation of 
perforin-independent killing in E7KC (Figure 6C).
Likewise, although TNFα inhibition of perforin-
sufficient T cells abrogated KC death, in perforin-
deficient co-cultures, the reduction in KC death was much 
less, implying that perforin-mediated killing was more 
dependent on TNFα than perforin-independent killing. 
Additional inhibition of Fas was not protective of E7KC 
death by perforin-sufficient CTL and did further impede 
killing by perforin-deficient CTL. (Figure 6D).
IFNγ has been shown to enhance cytotoxic killing of 
target cells by inducing antigen expression and increased 
Figure 5: Increased levels of PD-L1 expression by E7KC is protective. Co-cultures of CTL and SIINFEKL-loaded B6KC 
or E7KC were treated with anti-PD-L1 antibody or isotype control antibody. (A) Death of KC in co-culture with effectors (black) or as 
monocultures (grey), or in co-cultures without PD-L1 inhibition (white). (B) CTL-target attachment duration. (C) CTL death in co-cultures. 
(D) Flow cytometry of primary KC harvested as in Figure 4E, and stained for PD-L1 expression using the same gating strategy. Isotype 
control is also shown. (E) Primary KC were cultured for 5 days and cell lysates were harvested for RNA extraction and subject to RT-PCR 
for PD-L1 mRNA quantification. Each value is one mouse. (*p<0.05).
Figure 6: Hierarchical killing of KC by CTL is altered by E7 expression. T cell killing mechanism hierarchy was investigated 
by inhibition of multiple pathways during co-culture of primary non-transgenic KC (B6) or E7-expressing KC (E7) loaded with constant 
amount of peptide and perforin-competent or Prf1-/- effector CD8 T cells. Co-cultures were incubated with anti-Fas (A), or anti-FasL (B) 
inhibitory antibody. (C) Co-cultures of effector and target cells were incubated with anti-PD-L1 inhibitory antibody, with or without Fas 
inhibition. (D) Co-cultures were treated with anti-TNFα antibody with or without Fas inhibition. (E) Co-cultures were treated with anti-
IFNγ with, or without, Fas inhibition. Average values of five imaging sites of duplicate wells for each experiment are shown as one dot. 
(*p<0.05) Data from single inhibitor experiments Figure 2-5 have been reshown in these graphs for ease of comparison. Note that the ‘+’ 
indicates the functional presence of the particular cytokine while ‘–’ indicates its absence by knock-out or by antibody (e.g. If Fas is present, 
there is a ‘+’, while Fas inhibition with antibody is indicated by ‘–’).
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cytokine production. In immune-mediated killing of E7-
expressing KC, its role in vivo appears to be inhibitory 
[24]. In vitro, inhibition of IFNγ did not significantly affect 
CTL killing of E7KC (Figure 6E), but inhibiting Fas in this 
environment increased E7 target cell loss, suggesting the 
protective effect of Fas on E7 killing is independent of IFNγ. 
In the absence of perforin, on the other hand, inhibition of 
IFNγ abrogated killing. These data suggest IFNγ plays a role 
in the perforin-independent killing of E7KC.
Based on these tests, we ranked the mechanisms 
of killing used by CTL to achieve target cell death of 
B6 and E7KC. CTL killing of non-transgenic KC relies 
predominantly on perforin and appears to be licensed 
by TNFα. Further down the hierarchy, but playing an 
important role are IFNγ and the Fas/FasL system, while 
PD1/PD-L1 system plays no role in KC killing. TNFα 
plays a key role among the mechanisms CTL used to 
kill E7KC. Ranked below this, and equally significant in 
vitro are IFNγ and perforin, while the Fas/FasL system 
and PD1/PD-L1 system offer some protection for E7KC 
against these mechanisms. The percentage of killing of 
E7KC that is perforin-independent may be due to IFNγ or 
the Fas/FasL system, while TFNα plays only a minor role 
in this system (Figure 7).
DISCUSSION
CD8 T cells, the primary effector cells in tumor 
eradication, utilize a variety of seemingly overlapping 
and redundant mechanisms to effect target cell death, 
both contact-dependent and contact independent, a trait 
particularly important to their anti-viral functions [25]. 
The relationships between these redundant mechanisms 
are highly complex and likely offer an evolutionary 
advantage. Here we show that these mechanisms can be 
used hierarchically in response to oncogene expression. 
This study does not examine the effect of priming and the 
response of the T cell to the specific antigen expressed 
by the target cell, rather it examines how expression of 
the oncogene alters protein expression within the cell to 
require effector T cells to utilize different mechanisms of 
killing in order to effect target cell death.
CD8 T cells are known to predominantly use 
perforin to kill target cells. Earlier studies identified 
TNFα-mediated killing mechanisms as equally significant 
in achieving target cell death, in both infectious and non-
infectious models [26, 27], which we confirm here. We 
also found that with non-oncogene expressing KC, IFNγ 
and Fas/FasL were less critical to achieve target cell death, 
and supplemented the primary mechanisms. Fas and 
IFNγ have been reported to be more important in killing 
pancreatic beta cells in T-cell dependent murine models 
of diabetes mellitus [28] although TNFα assistance was 
essential [23], as was also confirmed in this model.
The factors that determine the choice of mechanism 
used by CD8 effector cells to achieve target cell death 
remain unclear. Target cell type likely plays an important 
part, as death is determined by the concentration of specific 
receptors on the target cell surface such as FasL, IFNγR 
and negative ligands such as Fas and PD-L1. Keratinocyte 
Figure 7: E7 expression by KC alters hierarchy of killing mechanisms used by CTL. Putative differences in the hierarchy 
of killing mechanisms used by CTL to kill KC expressing E7 compared with non-transgenic B6KC targets as modeled by in vitro killing 
studies in this study. Cytokines inhibitory to a specific killing mode are indicated by dotted lines. Without oncogene expression, B6KC 
were killed predominantly by perforin and TNFα mediated mechanisms, both of which were essential, while Fas/FasL and IFNγ were less 
important modes of killing. PD-L1 is not expressed in B6KC, and blockade had no effect on killing, and this has been excluded from the 
diagram. With expression of E7 oncogene, E7KC still require TNFα as essential for killing. Less significantly, IFNγ and perforin contribute 
to killing targets. IFNγ-independent killing does take place, but it appears not to be mediated by any of the processes we examined here. 
Perforin-independent killing is reliant on Fas/FasL or on IFNγ. PD1/L1 contributes to target cell death perforin-independent killing, but 
along with Fas/FasL, inhibits killing by IFNγ and perforin in perforin-sufficient T cells.
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susceptibility to non-perforin mediated killing is markedly 
up-regulated in the absence of PD-1/PD-L1 interaction 
[29], suggesting that redundant killing mechanisms are 
preferentially up-scaled when primary mechanisms are not 
available. Additionally, the inflammatory environment and 
cytokine milieu may play a key role in determining the 
actions of infiltrating effector cells. Extreme inflammatory 
environments lead to large amounts of locally produced 
TNFα and IFNγ which, in addition to being cytotoxic to 
KC directly, also up-regulate Fas-mediated KC death [30, 
31]. The strength of the signal to T cells has also been 
implicated in determining the mechanism of cell death, 
with high-affinity ligands leading to perforin-mediated 
killing while low affinity ligands utilize slower perforin-
independent pathways [32]. Additionally, the use of 
perforin and Fas by CTL has been associated with strength 
of priming in antigen-specific killing and Fas expression 
may improve perforin-mediated killing [33, 34].
Pathogenic organisms, such as viruses, adapt 
their host cell to avoid being killed rapidly by perforin, 
which may leave them more susceptible to slower Fas/
FasL interaction for eradication [35], thus giving the 
organism time to replicate and disseminate. In this study, 
utilization of Fas/FasL resulted in markedly increased 
contact time between effector and target cells. In the E7 
transformed KC with its increased rate of replication, this 
may represent a mechanism for immune cells to escape 
killing by Fas. We speculate that the prolonged contact 
time required for Fas-mediated killing may promote 
modalities of cellular escape by target cells during this 
phase of attachment such as alteration of membrane 
dynamics during mitosis. The effects of target cell mitosis 
on immunological killing mechanisms is unknown and we 
suggest the utilization of imaging techniques is assessing 
effector-target contact in tumors is a useful in assessing 
this further. In addition, FasL expression on endothelial 
cells has been shown to delay T cell migration into 
tumours and may have an effect on T cell motility which 
we have previously shown is directly related to tumour 
killing ability by these cells [18, 36].
HPV E7 expression confers changes upon host 
keratinocytes that may have had a growth advantage for the 
virus which persist upon transformation. In immortalized cell 
lines and transformed KC, E7 expression confers resistance 
to the direct cytostatic effects of TNFα possibly by the up-
regulation of cell cycling and replication due to the action 
of E7 on the retinoblastoma gene [10, 37]. We did not assess 
KC replication in our model, but suggest additionally that 
oncogenes such as E7 may alter the expression levels of 
surface markers reliant on TNFα stimulation, such as Fas and 
IFNγR, which are required for CD8 T cell mediated killing. 
This is also supported by evidence that the addition of TNFα 
to tumor cells increases their susceptibility to Fas-mediated 
killing by effector cells [38].
HPV-related cervical cancer and head and neck 
cancers are associated with increased expression of PD-
L1, which is associated with dysfunction of the T cell 
immune response to these tumors [16, 39]. We show here 
that E7 expression on KC is sufficient to up-regulate of 
these negative receptors resulting in both KC protection 
and in increased death of effector cells, promoting a fight-
back response. Tumors are associated with a infiltration 
of T cells displaying varying degrees of exhaustion 
[40], characterized by low levels of perforin and IFNγ 
expression, and increased expression of negative regulators 
such as PD1. Thus perforin-independent mechanisms of T 
cell killing become important in maintaining some degree 
of anti-tumor activity. Interestingly, IFNγ-independent 
killing of E7KC took place that is not dependent on 
any of the other methods of killing we have examined 
here, emphasizing that CD8 T cells have an extensive 
armamentarium of killing, and we have explored only 
some of the major ones in this study. Molecules such 
as Tim-3 have shown increasing promise as therapeutic 
targets and remain to be explored [41].
Understanding the changing nature of susceptibility 
to immune-modulated killing mechanisms due to oncogene 
expression holds the key to optimizing immunotherapy 
for HPV-related cancers. Using a protease inhibitor to 
sensitize tumors to apoptosis resulted in enhanced IFNγ 
production, increased Fas expression and improved tumor 
lysis in vivo [42]. Likewise, inhibition of PD1/L1 reduces 
T cell death and improves eradication of HPV-related 
tumors in immunomodulatory therapy [43]. Recently, an 
anti-CD40 based vaccine against E7 was able to prime 
T cells to kill HPV-related tumor cells, suggesting that 
once cytotoxic T cells are primed against E7 targets, their 
killing may be optimized to achieve strong tumorcidal 
efficacy [17]. Additionally, chemotherapeutic agents may 
be immunologic sensitizers to immunotherapy, modulating 
cancer targets for better recognition and killing [44]. 
Optimization measures could include a combination of 
blockade of negative regulators Fas/FasL and PD1/L1, 
along with cell sensitization therapies to improve IFNγ 
and perforin-mediated killing. Further investigation of 
IFNγ-independent killing of E7-expressing KC may lead 
to more therapeutic targets.
In this study, we employed a minimalist model in 
vitro using primary murine cells to examine the relative 
importance of several redundant killing mechanisms used 
by cytotoxic T cells in effecting tumour cell death. These 
mechanisms may reflect only part of the interactions in 
vivo in human disease in which levels of inflammatory 




All experiments were approved by the University 
of Queensland animal ethics committee. K14.E7 mice 
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from a B6 background were bred in-house. Rag1-/- mice 
were purchased from the Animal Resource Centre, Perth, 
Australia. B6.Nzeg mice express a nuclear-localised 
enhanced green fluorescent protein (EGFP) and were 
provided by K. Matthaei, Australian National University. 
B6.Prf1-/- mice were bred with B6.Nzeg mice to generate 
Prf1-/-. Nzeg mice, also expressing EGFP.
Reagents
Anti-CD44, anti-IFNγ, anti-CD8, relevant isotype 
antibodies as well as inhibitory antibodies to Fas, FasL, 
TNFα, and INFγ were purchased from BD Pharmingen. 
Anti-CD62L was from eBioscience. Recombinant IFNγ 
was purchased from R&D Systems. Z-DVED-FMK and 
ovalbumin (OVA) were purchased from Sigma. Media for 
cell culture and IL-2 was purchased from Invitrogen.
Keratinocyte culture
Primary KC were harvested from 3-4 day old E7 and 
B6 mice as described [13]. Keratinocytes were cultured 
in 24-well culture plates (allocating 12 wells to each KC 
type) in DMEM with 5% fetal bovine serum for 24 hours 
before changing to Serum-Free Media supplemented with 
bovine pituitary extract and epidermal growth factor. The 
24-well plate of KC was imaged when the cells were 70% 
confluent.
Harvest of CD8 T cells
EGFP+ mice were immunised by subcutaneous 
injection with 50 μg of OVA, and Quil A (20 μg). 
Splenocytes were harvested one week later, and stained 
with anti-CD8, before FACS to obtain a >98% pure 
population of GFP+CD8+ cells. These were further cultured 
for three days in the SIINFEKL peptide, the minimal 
CTL epitope of OVA, and IL-2 to further select for OVA-
specific CD8 T cells.
Co-culture
C57 and E7KC were loaded with 1 μg.ml-1 of 
SIINFEKL peptide for 60 min at 37ºC once they reached 
70% confluence in culture on 24-well plates. KC were 
extensively washed in warm PBS before co-culturing 
with effector cells. We added 5 ×103 EGFP+CD8+ T 
cellsper well into duplicate wells of keratinocytes, giving 
an approximate target:effector ratio of 10:1. Cells were 
imaged at 37°C with 5% CO2 for 30 h in 50% serum-
free medium, 45% RPMI, 5% fetal bovine serum, 5 ng.
ml−1 IL-2 and 2% SR-FLIVO solution. We included 
control wells of KC monocultures in each plate, as well 
as co-cultures without peptide loading, to assess baseline 
KC death and ensure there was no non-antigen specific 
killing as previously described [18]. Inhibitory antibodies 
or isotype control antibodies were added to the KC 
at the time of CTL addition unless stated otherwise. In 
pre-incubation experiments, KC were incubated with 
antibodies or isotype controls for 60 min and cells were 
then washed four times with media prior to the addition 
of CTL.
Cell killing assay
As previously, activation of intracellular caspases 
was noted by a color change in the cells mediated by cell-
permeant SR-FLIVO red (courtesy of Immunochemistry 
Laboratories), as determined by image analysis software 
[18]. Rates of KC death of cells were determined by size 
(>12 μm for KC and <10 μm for T cells), and expressed as 
a percentage of number of cells of that type visible at time 
0. We used at least 3 fields of view per well of duplicate 
wells from at least 3 replicated experiments.
RNA analysis
Ear skin samples were lysed into RNase-free 
microtubes in 1ml of Trizol (Sigma) and RNA extracted 
according to manufacture’s instructions. The RNA pellet 
was washed twice in 70% ethanol and air-dried before 
resuspension and genomic DNA was then digested as 
per manufacturer (Qiagen). RNAs were quantified by 
nanodrop spectrophotometry. For retro-transcription, 500 
ng of RNA combined with 25 mM MgCl2, 25 mM dNTPs, 
oligoDT, RNase inhibitor, and MuLV Taq polymerase in 
its buffer for 25 min at 25°C, 60 min at 42°C and 5 min at 
95°C. Samples were amplified using Sybr premix Taq II 
(TAKARA) on ABI7900 (Applied Biosystems) - 1x 30 s at 
95°C, 45x (5s 95°C and 30 s at 60°C), followed by (15 s at 
95°C, 60 s at 60°C, 15 s at 95°C). Primers were designed 
using Integrated DNA Technologies.
Immunofluorescence
Cells for flow cytometry were prepared by 
trypsination of co-cultures, followed by viability staining, 
and then surface staining with anti-Fas or anti-FasL 
antibody or isotype-specific negative controls at 4ºC before 
running on BD FacsCanto with Diva software. Semi-
quantitative analysis was determined only as a percentage 
of total cells by flow cytometry. For microscopy studies, 
co-cultures were performed on chamber slides, which 
were then harvested, fixed in 1% paraformaldehyde and 
stained for surface antigen expression.
Microscopy
Confocal microscopy was performed on a Zeiss 
Meta-510 confocal microscope using Zen software, with 
×25 oil-immersion objective lens. Time-lapse microscopy 
was performed on a Zeiss Axiovert 200M microscope 
with a ×10 objective lens. Images were acquired from five 
fields of view per well from duplicate wells every 12 min 
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for 30 h. Cells were maintained with humidification, in 
5% CO2, at 37°C during imaging by specialized enclosure 
built around the microscope.
Image analysis
Imaris software was used to de-convolve and 
analyze raw images, and generate movies. Death of 
KC and T cells was determined by caspase-3 activation 
and resultant red color change. Statistical analysis was 
performed using Excel and Graphpad Prism. To prepare 
images for publication, cropping, a median filter (3×3), 
and minor contrast adjustments were made using Adobe 
Photoshop or Imaris.
Statistics
Data were collected from 5 sites each from 
duplicate wells and averaged giving a single value for 
each experiment, and experiments were repeated at least 
3 times. We used the one-tailed Mann-Whitney test, 
or one-way ANOVA to compare non-parametric data. 
We accepted p < 0.05 as showing significant difference 
between groups.
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